ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.078
+$0.003 (+4.00%)
Day Range
$0.075 – $0.078
52 Week Range
$0.052 – $0.155
Volume
1.89K
Avg Volume (10D)
51.28K
Market Cap
$28.76M
Price Chart
Market Statistics
Open$0.075
Previous Close$0.075
Day High$0.078
Day Low$0.075
52 Week High$0.155
52 Week Low$0.052
Valuation
Market Cap28.76M
Shares Outstanding368.68M
Price to Book11.49
Trading Activity
Volume1.89K
Value Traded144.38
Bid$0.075 × 5,836
Ask$0.078 × 40,000
Performance
1 Day4.00%
5 Day-1.27%
13 Week-8.24%
52 Week16.42%
YTD-25.71%
Technical Indicators
RSI (14)53.33
50-Day SMA$0.075
200-Day SMA$0.092
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.